Indicators of drug-seeking aberrant behaviours: The feasibility of use in observational post-marketing cohort studies for risk management

Drug Safety

Volumn 37, Issue 8, 2014, Pages 639-650

  Layton, Deborah ^a,b   Osborne, Vicki ^a,b   Al Shukri, Mohammad ^a   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL;

ARTICLE; BEHAVIOR DISORDER; COHORT ANALYSIS; DRUG ABUSE; DRUG DEPENDENCE; DRUG SEEKING BEHAVIOR; DRUG SURVEILLANCE PROGRAM; HUMAN; MAJOR CLINICAL STUDY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; ADULT; AGED; BEHAVIOR, ADDICTIVE; DRUG MISUSE; FEASIBILITY STUDY; FEMALE; MALE; MIDDLE AGED; OBSERVATION; OPIOID-RELATED DISORDERS; PREVALENCE; PROCEDURES; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM;

ADULT; AGED; BEHAVIOR, ADDICTIVE; COHORT STUDIES; ENGLAND; FEASIBILITY STUDIES; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; OBSERVATION; OPIOID-RELATED DISORDERS; PHARMACOVIGILANCE; PRESCRIPTION DRUG MISUSE; PREVALENCE; RISK MANAGEMENT;

EID: 84906315137     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0193-4     Document Type: Article

References (47)

1. European Medicines Agency. New 2010 EU pharmacovigilance legislation. European Medicines Agency [online] Available at http://www.ema.europa.eu/ema/ index.jsp?curl=pages/regulation/general/general-content-000492.jsp&mid= WC0b01ac058033e8ad&jsenabled=true. Accessed 12 Dec 2013.
2. Food and Drug Administration. Guidance for industry. Development and use of risk minimisation action plans 2005 [online]. Available at http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126830.pdf. Accessed 12 Dec 2013.
3. World Health Organisation. Management of substance abuse. Abuse (drug, alcohol, chemical, substance or psychoactive substance) definition 2012 [online]. Available at http://www.who.int/substance-abuse/terminology/abuse/en/ index.html. Accessed 12 Dec 2013.
4. Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012;15(3 Suppl):ES67-92.
5. National Institutes of Health. National Institute on Drug Abuse (NIDA) research report series: prescription drug abuse. 2011 [online]. Available at http://www.drugabuse.gov/sites/default/files/rxreportfinalprint.pdf.Revised. Accessed 12 Dec 2013.
6. European Medicines Agency. Guideline on good pharmacovigilance practices. Module VI: management and reporting of adverse reactions to medicinal products. 2012 EMA/873138/2011[online]. Available at http://www.emea.europa.eu/docs/en- GB/document-library/Scientific-guideline/2012/06/WC500129135.pdfDate. Accessed 2 Jul 2012.
7. Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154(11):2287-96.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013.
9. Solanki DR, Koyyalagunta D, Shah RV, Silverman SM, Manchikanti L. Monitoring opioid adherence in chronic pain patients: assessment of risk of substance misuse. Pain Physician. 2011;14(2):E119-31.
10. Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):131-46.
11. European Medicines Agency. Guideline on good pharmacovigilance practices. Module VI: management and reporting of adverse reactions to medicinal products. EMA/873138/2011[online]. Available at http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2012/02/WC500123203.pdf. Accessed 20 Jul 2012.
12. European Medicines Agency. Guideline on good pharmacovigilance practices. Module IX: signal management. EMA/827661/ 2011 [online]. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/ 02/WC500123209.pdf. Accessed 20 Jul 2012.
13. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Approval package: FENTORA (fentanyl citrate) tablets. 2008 Application No.: 021947 [online]. Available at http://www.fda.gov/cder/foi/label/2008/ 021947s006lbl.pdf. Accessed 12 Aug 2008.
14. European Medicines Agency. European Medicines Agency Preauthorisation Evaluation of Medicines for Human Use. CHMP Summary of Positive Opinion for EFFENTORA Doc Ref: EMEA//34716/2008 [online]. Available at http://www.emea. europa.eu/pdfs/human/opinion/Effentora-3471608en.pdf. Accessed 12 Aug 2008.
15. European Medicines Agency. 2008 EMEA European Public Assessment Report (EPAR) EFFENTORA Doc Ref: EMEA/H/C/833 [online]. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/effentora/H-833-en1.pdf. Accessed 12 Aug 2008.
16. Solanki D, Koyyalagunta D, Shah R, Silverman S, Manchikanti L. Monitoring opioid adherence in chronic pain patients: assessment of risk of substance misuse. Pain Physician. 2011;14:E119-31.
17. Atluri S, Sudarsham G. Development of a screening tool to detect the risk of inappropriate prescription opioid use in patients with chronic pain. Pain Physician. 2004;7:333-8. (Pubitemid 39206371)
18. Chabal C, Erjavec MK, Jacobson L, Mariano A, Chaney E. Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors. Clin J Pain. 1997;13(2):150-5. (Pubitemid 27251109)
19. Layton D, Shakir SAW. Prescription-event monitoring. In: Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. 5th ed. Chichester, UK: John Wiley & Sons Ltd.; 2011. p. 301-30.
20. ICH Harmonised Tripartite Guideline. Post-approval safety data management: definitions and standards for expedited reporting E2D. 2003. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E2D/Step4/E2D-Guideline.pdf. Accessed 23 June 2014.
21. Edlund MJ, Sullivan M, Steffick D, Harris KM, Wells KB. Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers? Pain Med. 2007;8(8):647-56. (Pubitemid 350142912)
22. Edlund MJ, Steffick D, Hudson T, Harris KM, Sullivan M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain. 2007;129(3):355-62. (Pubitemid 46754578)
23. The American College of Occupational and Environmental Medicine. Guidelines for the chronic use of opioids. 2008 revised 2011 [online]. Available at http://www.acoem.org/uploadedFiles/Knowledge-Centers/Practice-Guidelines/ Chronic%20Pain%20Opioid%202011.pdf. Accessed 12 Aug 2013.
24. Ballantyne JC, LaForge KS. Opioid dependence and addiction during opioid treatment of chronic pain. Pain. 2007;129(3): 235-55. (Pubitemid 46754581)
25. British Medical Association Board of Science, British Medical Association Science and Education. Reporting adverse drug reactions: a guide for healthcare professionals, 2006. London, UK [online]. Available at http://bmaopac.hosted. exlibrisgroup.com/exlibris/aleph/a21-1/apache-media/ GYVFNJ1RT2PFNDUJ8IUKPUNTFVRF8G.pdf. Accessed 31 May 2006.
26. Council for International Organizations of Medical Sciences (CIOMS), World Health Organisation (WHO). International ethical guidelines for biomedical research involving human subjects. Geneva, Switzerland: 2002 [online]. Available at http://www.cioms.ch/publications/layout-guide2002.pdf. Accessed 12 Dec 2013.
27. General Medical Council. Confidentiality. 2009 [online]. Available at http://www.gmc-uk.org/static/documents/content/Confidentiality-0910.pdf. Accessed 08 Jul 2011.
28. General Medical Council. Confidentiality: disclosing information for education and training purposes. 2009 [online]. Available at http://www.gmc-uk.org/Confidentiality-disclosing-info-education-2009. pdf-27493403.pdf. Accessed 11 Jul 2011.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Arlington (VA): American Psychiatric Association; 2007.
30. Collett BJ. Chronic opioid therapy for non-cancer pain. Br J Anaesth. 2001;87(1):133-43.
31. Fine RL. Ethical and practical issues with opioids in life-limiting illness. Proc (Bayl Univ Med Cent). 2007;20(1):5-12.
32. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/ or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444-59. (Pubitemid 351722518)
33. Nicholson B, Passik SD. Management of chronic noncancer pain in the primary care setting. South Med J. 2007;100(10):1028-36. (Pubitemid 47537888)
34. Katz NP, Adams EH, Benneyan JC, Birnbaum HG, Budman SH, Buzzeo RW, et al. Foundations of opioid risk management. Clin J Pain. 2007;23(2):103-18. (Pubitemid 46145457)
35. American Academy of Pain Medicine. Definitions related to the use of opioids for the treatment of pain. WMJ. 2001;100(5):28-9.
36. Griffiths RR, Bigelow GE, Ator NA. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 2003;70(3 Suppl):S41-54. (Pubitemid 36577514)
37. Hedden SL, Woolson RF, Malcolm RJ. Randomization in substance abuse clinical trials. Subst Abuse Treat Prev Policy. 2006;1:6.
38. Arfken CL, Cicero TJ. Postmarketing surveillance for drug abuse. Drug Alcohol Depend. 2003;70(3 Suppl):S97-105.
39. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2: guidance. Pain Physician. 2012;15(3 Suppl):S67-116.
40. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part I: evidence assessment. Pain Physician. 2012;15(3 Suppl):S1-66.
41. British Pain Society. Opiods for persistent pain: good Practice. A consensus statement prepared on behalf of the British Pain Society, the Royal College of Anaethetists, the Royal College of General Practitioners and the Faculty of Addictions of the Royal College of Psychiatristis. 2010 [online]. Available at http://www.britishpainsociety.org/book-opioid-main.pdf. Accessed 12 Dec 2013.
42. Cone EJ. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend. 2006;83(Suppl 1):S31-9.
43. Savage SR. Assessment for addiction in pain-treatment settings. Clin J Pain. 2002;18(4 Suppl):S28-38. (Pubitemid 34815392)
44. Meltzer EC, Rybin D, Saitz R, Samet JH, Schwartz SL, Butler SF, et al. Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM). Pain. 2011;152(2):397-402.
45. McAvoy B, Kaner E. General practice postal surveys: a questionnaire too far? BMJ. 1996;313(7059):732-3.
46. Heeley E, Riley J, Layton D, Wilton L, Shakir S. Prescription-event monitoring and reporting of adverse drug reactions. Lancet. 2001;358(9296):1872- 3. (Pubitemid 34008656)
47. Martin R, Kapoor K, Wilton L, Mann R. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ. 1998;317(7151):119-20. (Pubitemid 28310619)